Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | HTR2C | P28335 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrazole SCHEMBL225087 | 1.00 | HTR2A (0.34) | HTR2AHTR1AHTR2CHTR2B | |
| Tetrazole SCHEMBL6037735 | 1.00 | HTR2A (0.34) | HTR2AHTR1AHTR2CHTR2B | |
| Tetrazole SCHEMBL526238 | 0.99 | HTR2A (0.33) | HTR2AHTR1AHTR2CHTR2B | |
| Tetrazole SCHEMBL5145009 | 0.90 | HTR2A (0.31) | HTR2AHTR1AHTR2CHTR2B | |
| O-Tolylamine SCHEMBL7116171 | 0.88 | HTR2A (0.32) | HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL23488 | 0.88 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL29356973 | 0.88 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL5058499 | 0.86 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2B | |
| Ammonia Solution, Strong SCHEMBL20492883 | 0.86 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2B | |
| SCHEMBL17668115 | 0.86 | HTR2A (0.40) | HTR2AHTR1AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080044928-A1 | Method for the Preparation of Ready-to-Use Support for Rapid Enzyme-Linked Immunosorbent Assay (Elisa) | MAHARASHTRA HYBRID SEEDS COMPANY LTD (IN) | 2008-02-21 | — | — | US | claimed |
| US-20250339417-A1 | BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS-CLOVES SYNDROME) | INST NAT SANTE RECH MED (FR) | 2025-11-06 | — | — | US | disclosed |
| US-12427141-B2 | BYL719 (alpelisib) for use in the treatment of PIK3CA-related overgrowth spectrum (PROS-CLOVES syndrome) | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2025-09-30 | — | — | US | disclosed |
| US-20250295645-A1 | BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS-CLOVES SYNDROME) | INST NAT SANTE RECH MED (FR) | 2025-09-25 | — | — | US | disclosed |
| US-12320804-B2 | Detection of cleavage activity of an enzyme | MOLOGIC LIMITED (GB) | 2025-06-03 | — | — | US | disclosed |
| US-20250157661-A1 | MONITORING INFLAMMATION STATUS | MOLOGIC LIMITED (GB) | 2025-05-15 | — | — | US | disclosed |
| EP-3830284-B1 | BACTERIAL VAGINOSIS DIAGNOSTIC | MOLOGIC LTD (GB) | 2025-02-19 | — | — | EP | disclosed |
| US-11953506-B2 | Monitoring inflammation status | MOLOGIC LIMITED (GB) | 2024-04-09 | — | — | US | disclosed |
| EP-3928100-B1 | TREATMENT STRATIFICATION FOR AN EXACERBATION OF INFLAMMATION | MOLOGIC LTD (GB) | 2023-03-22 | — | — | EP | disclosed |
| US-20220323428-A1 | BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS-CLOVES SYNDROME) | Université de Paris (FR) | 2022-10-13 | — | — | US | disclosed |
| WO-1992021980-A1 | DEVICES FOR PERFORMING ION-CAPTURE BINDING ASSAYS | ABBOTT LABORATORIES (US) | 1992-12-10 | — | — | WO | disclosed |
| EP-0467078-A2 | An analyte-subtitute reagent for use in specific binding assay methods, devices and kits | ABBOTT LABORATORIES (US) | 1992-01-22 | — | — | EP | disclosed |
| EP-0462376-A2 | Conjugate recovery binding assays | ABBOTT LABORATORIES (US) | 1991-12-27 | — | — | EP | disclosed |
| US-5075078-A | SELF-PERFORMING IMMUNOCHROMATOGRAPHIC DEVICE | ABBOTT LABORATORIES (US) | 1991-12-24 | — | — | US | disclosed |
| EP-0440044-A1 | Avoidance of human anti-mouse antibody interference in in vitro diagnostic testing | ABBOTT LABORATORIES (US) | 1991-08-07 | — | — | EP | disclosed |
| EP-0421294-A2 | Improved self-performing immunochromatographic device | ABBOTT LABORATORIES (US) | 1991-04-10 | — | — | EP | disclosed |
| EP-0406473-A1 | Ion capture reagents and methods for performing binding assays | ABBOTT LABORATORIES (US) | 1991-01-09 | — | — | EP | disclosed |
| EP-0351804-A2 | HCG peptides for use in antibody purification procedures | ABBOTT LABORATORIES (US) | 1990-01-24 | — | — | EP | disclosed |
| EP-0323605-A2 | Chromatographic binding assay devices and methods | ABBOTT LABORATORIES (US) | 1989-07-12 | — | — | EP | disclosed |
| EP-0251527-A2 | Haptenylated reagents and immunoassays | Panab Laboratories, Inc. (US) | 1988-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339417-A1 | BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS-CLOVES SYNDROME) | PIK3C3, PIK3CA, PIK3C2B | HTR2A 4813/4885HTR1A 4701/4885HTR2C 4869/4885 |
| US-12427141-B2 | BYL719 (alpelisib) for use in the treatment of PIK3CA-related overgrowth spectrum (PROS-CLOVES syndrome) | PIK3C3, PIK3CA, PIK3C2B | HTR2A 4813/4885HTR1A 4701/4885HTR2C 4869/4885 |
| US-20250295645-A1 | BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS-CLOVES SYNDROME) | PIK3C3, PIK3CA, PIK3C2B | HTR2A 4813/4885HTR1A 4701/4885HTR2C 4869/4885 |
| US-20220323428-A1 | BYL719 (ALPELISIB) FOR USE IN THE TREATMENT OF PIK3CA-RELATED OVERGROWTH SPECTRUM (PROS-CLOVES SYNDROME) | PIK3C3, PIK3CA, PIK3C2B | HTR2A 4813/4885HTR1A 4701/4885HTR2C 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.